Previous close | 1.0000 |
Open | 1.0000 |
Bid | 0.0000 |
Ask | 5.0000 |
Strike | 20.00 |
Expiry date | 2024-09-20 |
Day's range | 1.0000 - 1.0000 |
Contract range | N/A |
Volume | |
Open interest | 6 |
If approved, Zeno will be the first targeted therapy for NRG1+ cancerUTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for the bispecific antibody zen
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merus (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.